Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-based induction followed by VMP versus high-dose melphalan/ASCT, with or without VRD consolidation, in newly diagnosed multiple myeloma
ACTRN12612000419864Phase 3Completed
- Sponsor
- HOVON
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, melphalan, lenalidomide, cyclophosphamide, dexamethasone and 1 more in multiple myeloma (MM) (4 arms), sponsored by HOVON. Primary endpoints: Progression-free survival for randomization 1 and Progression-free survival for randomization 2. Started Sep 2013; status: completed.
02
Drugs
bortezomibmelphalanlenalidomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12612000419864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000419864.